Novel inhibitors of epidermal growth factor receptor: (4-(Arylamino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)(1H-indol-2-yl)methanones and (1H-indol-2-yl)(4-(phenylamino)thieno[2,3-d]pyrimidin-6-yl)methanones |
| |
Authors: | Beckers Thomas Sellmer Andreas Eichhorn Emerich Pongratz Herwig Schächtele Christoph Totzke Frank Kelter Gerhard Krumbach Rebekka Fiebig Heinz-Herbert Böhmer Frank-D Mahboobi Siavosh |
| |
Affiliation: | Department of Pharmaceutical Chemistry I, University of Regensburg, D-93040 Regensburg, Germany. |
| |
Abstract: | Several members of the quinazoline class of known tyrosine kinase inhibitors are approved anticancer agents, often showing selectivity for receptors of the HER/ErbB-family. Combining structural elements of this class with the bisindolylmethanone-structure led to a series of novel compounds. These compounds inhibited EGFR in the nanomolar range. Moreover, inhibition of EGFR autophosphorylation in intact A431 cells was shown, with IC50 values ranging form 0.3–1 μM for compound 42, and 0.1–0.3 μM for 45. In a panel of 42 human tumor cell lines the sensitivity profile of the novel compounds was shown to be similar to that of the quinazoline class of tyrosine kinase inhibitors lapatinib and erlotinib (Tarceva®). |
| |
Keywords: | |
本文献已被 ScienceDirect PubMed 等数据库收录! |
|